1GONALVES G A PRATHER, K L MONTEIRO G A et al. En-gineering of Escherichia coli strains for plasmid biopharmaceuti-cal production: Scale-up challenges[J]. Vaccine, 2014.
2中国兽用生物制品规程(兔病毒性出血症灭活疫苗制造及检验规程;),2000版.
3ABRANTES J W Rabbit haemorrhagic disease (RHD) and rabbithaemorrhagic disease virus (RHDV): a review [J]. Veterinary re-search, 2012, 43(1):2879-2981.
4CRISCI E, BARCENA J, MONTOYA M Virus -like particles:The new frontier of vaccines for animal viral infections [J]. Vet-erinary Immunology and Immunopathology, 2012, 148 (3 -4):211-215.
6ERLINDA F, R. Conformational and thermal stability improve-ments for the large -scale production of yeast -derived rabbithemorrhagic disease virus-like particles as multipurpose vaccine[J]. PloS One, 2013,8(2):56417.
7CHEN, M, SONG Y FAN Z, et al. Immunogenicity of differentrecombinant rabbit hemorrhagic disease virus-like particles car-rying CD8+ T cell epitope from chicken ovalbumin (OVA)[J].Vims Research, 2014, 183.
8FERNANDEZ E,TOLEDO J R, ChlONG M, et al. Single doseadenovirus vectored vaccine induces a potent and long -lastingimmune response against rabbit hemorrhagic disease virus afterparenteral or mucosal administration [J]. Vet Immunol Im-munopathol, 2011, 142(3-4): 179-188.
9ROHDE J, SCHIRMEIER H, GRANZOW, H, et al. A new re-combinant Orf virus (ORFV, Parapoxvirus) protects rabbits a-gainst lethal infection with rabbit hemorrhagic disease virus(RHDV)[J]. Vaccine, 2011,29(49): 9256-9264.
10MIKSCHOFSKY H, SCHIRRMEIER, H, KATZEL A,et al. Ex-pression of truncated CTB::VP60 in tobacco exhibited no im-munogenicity in rabbits[J]. Plant Sci, 2011, 180(2): 246-250.
